Tazemetostat
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Follicular
Conditions
Lymphoma, Follicular
Trial Timeline
Aug 16, 2021 → Mar 31, 2028
NCT ID
NCT05228158About Tazemetostat
Tazemetostat is a pre-clinical stage product being developed by Eisai for Lymphoma, Follicular. The current trial status is active. This product is registered under clinical trial identifier NCT05228158. Target conditions include Lymphoma, Follicular.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Follicular were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05228158 | Pre-clinical | Active |
| NCT03456726 | Phase 2 | Completed |
| NCT03009344 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Follicular